Novartis to uncover different oncology authorization during ASCO

<p>ZURICH (Reuters) – Swiss drugmaker <span>Novartis</span> is anticipating pivotal <span>cancer</span> information on both a marketed products as good as earnest drugs in a early tube will uncover it can container a punch in a oncology margin during a vital attention assembly after this week.</p>
<p> The Basel-based group, that trails internal opposition Roche in oncology, will benefaction late-stage information on a drug Afinitor in postmenopausal women with modernized <span>breast cancer</span> as good as dual late-stage studies on a blood cancer drug Tasigna in patients with Philadelphia chromosome-positive ongoing myeloid leukaemia.</p>
<p> In addition, Novartis will benefaction a slew of early-stage information on compounds to provide a accumulation of diseases, including non-small dungeon <span>lung cancer</span>, <span>metastatic breast cancer</span>, NRAS-melanom...